Xpert® MTB/RIF Ultra
Detection of Mycobacterium tuberculosis complex and Rifampin resistance-associated mutations in 80 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
50 Tests
Unit price
Product is not available for purchase in your region.
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Each day, close to 4,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease1
  • Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected1
  • Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
(1) World Health Organization. Global Tuberculosis Report 2020. https://www.who.int/publications/i/item/9789240013131
(2) Kox. Tests for detection and identification of mycobacteria. How should they be used? Respir Med. 1995 Jul;89(6):399-408.;
(3) Diel et al. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals. Eur Respir J. 2016 Feb;47(2):575-87.;
(4) Behr et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999 Feb 6;353(9151):444-9.

The Solution

  • Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
  • Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients3
  • Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
  • Designed to provide the most accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
  • Accurate detection of mixed infections
(5) Jones M, et al. Xpert® MTB/RIF Ultra - design and analytical performance of a second generation Xpert® MTB/RIF assay. Poster presented at ECCMID. 2016 April 9-12, Amsterdam, Netherlands

The Impact

  • Early detection of MTB and resistance to Rifampicin enables faster access to the most appropriate treatment for better patient outcomes4
  • Increased access to front-line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help limit community transmission5
  • Superior performance of Xpert MTB/RIF Ultra versus smear microscopy enables more people with MTB infections to be detected and treated earlier4
(7) Global Laboratory Initiative. GLI model TB diagnostic algorithms. Accessed Mar 2017. http://www.stoptb.org/wg/gli/assets/documents/GLI_algorithms.pdf;
(8) World Health Organization. European Tuberculosis Laboratory Initiative. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapid molecular diagnostic technologies. Accessed Mar 2017. http://www.euro.who.int/__data/assets/pdf_file/0006/333960/ELI-Algorithm.pdf;
(9) Global Laboratory Initiative. Planning for country transition to Xpert® MTB/RIF Ultra cartridges. Accessed Apr 2017. http://www.stoptb.org/wg/gli/assets/documents/GLI_ultra.pdf